Biocomposites invests in InfectoTest GmbH – developers of a bacterial-specific point-of-care test for periprosthetic joint infection (PJI)
InfectoSynovia is being developed to provide a high-accuracy bedside test that can diagnose PJI in less than five minutes
It is based on InfectoTest’s ability to detect the infection in tiny quantities of synovial fluid using a unique method of electrochemical analysis
The investment signifies Biocomposites’ ongoing commitment to providing products for the management of infection in bone and soft tissue
Keele, UK, 16 October 2024 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces that it has taken a minority-share interest in InfectoTest GmbH (InfectoTest), a biomedical company based in Berlin that is developing innovative point-of-care systems for the diagnosis of infectious diseases.
One of InfectoTest’s lead products in development is InfectoSynovia, a rapid and high-accuracy test that will detect a periprosthetic joint infection (PJI) in less than five minutes.